The top ten medical innovations of 2021 are out.

The Cleveland Clinic, the world's top medical center, recently named the Top 10 Medical Innovations of 2021.
Cleveland holds an annual Medical Innovation Summit and releases its top 10 medical innovations that will impact the industry in its second year, with this selection of innovative technologies/therapies, including CD20 targeted therapy ocrelizumab, a new drug for cystic fibrosis, Tri Kafta, hepatitis C pangene therapy, PARP inhibitors and other innovative drugs, involving hemoglobin disease, primary multiple sclerosis, cystic fibrosis, hepatitis C, prostate cancer, migraines and other diseases.
gene therapy for hemoglobinopathy (hemoglobinopathy) is a group of hereditary blood diseases caused by abnormal hemoglobin molecular structure (abnormal hemoglobin disease) or abnormal rate of globin peptide chain synthesis (globin-producing disordered anemia).
Clinically, hemolytic anemia, high-iron hemoglobinemia, or cyanosis caused by tissue hypoxia or an increase in compensated red blood cells due to increased or decreased hemoglobin oxygen affinity.
most common hemoglobin diseases include sickle cell disease and thalassemia, which affect more than 330,000 newborns worldwide each year.
recent years, a number of gene therapies for hemoglobin disease have been born, bringing hope to the field.
May 2019, the European Union conditionally approved Zynteglo (Lenti Globin, an autobiographical CD34 plus cell containing beta-T87Q globin-encoded genes) for bluebird bio-disposable gene therapy Zynteglo became the world's first gene therapy to treat TDT, priced at $1.77 million, for patients aged 12 and older who are non-beta 0/beta 0 genotype transfusion dependence β-thalassemia (TDT).
September, Bluebird Bio announced that the European Medicines Agency (EMA) had granted Zynteglo priority drug eligibility (PRIME) for the treatment of sickle cell disease (SCD).
, the EMA also granted Zynteglo the orphan drug (ODD) for SCD treatment.
addition, in January, the FDA granted Aruvant Sciences' ARU-1801 orphan drug (ODD) for the treatment of sickle cell disease (SCD), an improved fetal hemoglobin gene therapy developed for the treatment of sickle cell disease (SCD) and β thalassemia.
Primary multiple sclerosis treatment of the new drug multiple sclerosis (MS) is the most common central nervous demyelination disease, through inflammation and tissue damage to destroy the normal function of the brain, optic nerve and spinal cord, good in the optic nerve, spinal cord, brain trunk, clinical manifestations of visual impairment, muscle weakness, speech difficulties, severe fatigue, cognitive impairment, and ultimately lead to disability.
about 2.3 million MS patients worldwide, and there is no complete cure.
March 2017, the FDA approved Roche's single-resistant product, Ocrelizumab, for multiple sclerosis (RMS) and primary progressive multiples The treatment of sclerosis (PPMS), which makes it the first and only disease modification therapy to be approved for 2 types of multiple sclerosis at the same time, and the first and only disease modification therapy to treat PPMS.
Ocrelizumab is a humanized anti-CD20 monoclonal antibody, while CD20-B fine is thought to be associated with myelin and axon damage, Ocrelizumab selectively binds to CD20 on the surface of B cells without affecting stem cells or plasma cells, which can perform nerve protection functions.
Ocrelizumab is administered intravenously once every six months, and at the time of release, the drug was priced at $65,000 a year.
devices connected to smartphones are an important part of care for implantable devices such as pacemakers and defibrillators used to prevent or correct arrhythmic arrhythmics and arrhythmics.
in traditional treatments, remote monitoring of these devices is carried out through bedside consoles, transferring data to doctors.
millions of patients currently use devices such as pacemakers and defibrillators, but most lack basic understanding of the device's function and are less dependent on remote monitoring.
's Bluetooth-enabled pacemaker device, which connects to a smartphone, provides timely disconnections between patients and their heart treatment, and gives patients a deeper understanding of the health data provided by pacemakers, and delivers health information to doctors in a timely manner, allowing patients and doctors to interact more closely and efficiently.
cystic fibrosis treatment of new drug cystic fibrosis (CF) is a hereditary endocrine gland disease, mainly affecting the gastrointestinal and respiratory system, usually with chronic obstruction of lung lesions, abnormal exocrine function of the pancreas and abnormally elevated sweat electrolyte characteristics, CF is mainly due to coding cystic fibrosis trans-membrane conductive regulatory factor (CFTR) gene mutation, resulting in CFTR protein deficiency or functional defects.
October 2019, the FDA approved the listing of Vertex's combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for the treatment of at least one F508 mutation in the trans-membrane conductive regulatory factor (CFTR) gene for cystic fibrosis (CF) and is expected to treat 90 percent of CF patients with the age of ≥12.
U.S., Trikafta is expected to be priced at $311,000.
Hepatitis C universal treatment hepatitis C is a viral hepatitis C virus (HCV) infection, is one of the most common liver diseases, mainly through blood transfusions, needles, drug use and other transmission, according to the World Health Organization, the global HCV infection rate of about 3%, estimated that about 180 million people infected with HCV, about 35,000 new cases of hepatitis C each year.
hepatitis C can lead to chronic inflammatory necrosis and fibrosis in the liver, and some patients can develop cirrhosis and even hepatic cell carcinoma (HCC).
2016, the FDA approved Gilead's oral cocktail therapy Epclusa (sofosbuvir and velpatasvir), a gene 1 to 6 hepatitis C virus (HCV) infection associated with or without the treatment of libawelin, in which Sofebwe is a nucleotide analogue polymer inhibitor and velpatasvir is a generic gene NS5A inhibitor.
is also the first drug approved to treat all six genotype HCV infections.
, in July 2017, the FDA approved Gilead's Vosevi for the treatment of adult patients with chronic hepatitis C virus (HCV) 1-6 without cirrhosis (liver disease) or mild cirrhosis. A one-piece daily treatment with three fixed-dose ingredients, including 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir (a generic genotype NS3 protease inhibitor).
the emergence of universal hepatitis C therapy has greatly simplified the treatment of patients with hepatitis C, and is expected to reduce the enormous burden of HCV at the public health level.
addition, this year's Nobel Prize in Physiology or Medicine awarded three scientists who discovered the hepatitis C virus.
babies who improve lung function in premature babies (Bubble CPAP) are often underweight and infirm and often require specialized care, including ventilation for premature babies with IRDS.
for premature babies, surfactants are usually used in mechanical breathing, which can cause lasting lung damage and lead to the development of chronic lung disease.
, b-CPAP is a non-invasive breathing strategy that provides the newborn with continuous positive pressure of the air to maintain lung capacity while exhaling.
instead of constant pressure enhances safety and effectiveness, minimizing physical damage and stimulating lung growth during long-term use.
practices and policies to improve the accessability of telemedicme during the COVID-19 epidemic, telemedicme practices have been increasingly adopted.
support at the policy level has enabled an increasing number of virtual care models and telemedicme initiatives that not only accelerate patient access to health care, but also protect the safety of healthcare workers and community members.
these changes have also opened the door to telemedicme and facilitated the development of new projects.
The vacuum-induced postpartum filler to control postpartum bleeding is a serious postpartum complication, is one of the four major causes of maternal mortality, about 1% to 5% of women will have postpartum haemorrhage, postpartum haemorrhage in China has been the first cause of maternal mortality in recent years.
treatment for postpartum haemorrhage includes blood transfusions, medication, surgery, and even the need to have the uterus removed in an emergency.
the latest advances in the field are vacuum-induced uterine filling, a method that uses negative pressure from the uterus to collapse the bleeding chamber and cause the muscles to close blood vessels.
-induced devices provide clinicians with a new minimally invasive tool for treating postparto-natal complications and can be used in resource-poor developing countries to benefit more patients.
, the second most common cancer among men in the world after lung cancer, has the fifth highest mortality rate.
February 2020, Cancer published the global burden of prostate cancer online, with about 1.3 million new cases of prostate cancer worldwide in 2017, more than a third of which occurred in the United States, followed by China.
addition, due to early common symptoms, including frequent urination, difficulty urinating, night urine, etc., similar to the symptoms of prostatitis, a common chronic disease in older men, half of the patients were diagnosed at a late stage.
PARP (poly-adenosine phosphorus ribonase) is a key DNA repair enzyme that is activated when DNA damage breaks, thereby identifying and binding to the DNA fracture location to further activate and catalyz the polyADP ribonucleation of the protein and participate in the DNA repair process.
PARP inhibitors hinder the DNA repair process by affecting PARP function, resulting in the death of the defective cells of the same recombinant repair.
years, the research and development of PARP inhibitors has become a hot spot in the field of anti-cancer.
May 2020, the FDA approved two PARP inhibitors for the treatment of prostate cancer: Clovis Oncology's Rucaparib, for the treatment of adult patients with metastatic degenerative resistance prostate cancer (mCRPC) with BRCA gene mutations;
it's worth noting that Rubraca was the first PARP inhibitor approved for prostate cancer treatment.
Anti-migraine immunological migraine is the most common type of primary headache in clinical practice, clinical to the onset of moderate-severe, throbbing-like headache as the main manifestation, headache is mostly on the side, generally lasts 4 to 72 hours, can be accompanied by nausea, vomiting, light, sound stimulation or daily activities can aggravate the headache.
migraines are common in children and adolescents, peak incidence in middle and young age, female patients are three times as common as men, the prevalence rate in the population is 5%-10%, often with a genetic background.
estimates that there are about 1.3 billion migraine sufferers worldwide.
migraines can not and cure, relieve or terminate headache attacks, relieve associated symptoms and so on.
Currently common specific treatments include wheat horn preparations, qutan drugs, etc. , however, such drugs have a strong vasoconstrication effect, so patients at risk of cardiovascular disease can not use these drugs, while frequent use can also cause overuse headaches.
in recent years, the field of migraine treatment has ushered in a new breakthrough.
In 2018, researchers developed new drugs to help prevent migraines, which work by blocking the activity of calcitonin gene-related peptides (CGRP), which raise levels of CGRP in the blood when migraines strike, and CGRP released by the trident nervous system, which triggers migraine attacks.
this discovery makes the CGRP signaling pathrapy a popular target for the treatment of migraines, and several antibody therapies of the CGRP subject or CGRP itself have been approved worldwide for the prevention and treatment of migraines, including erenumab-aooe, fremanezumab-vfrm, galcanezumab-gnlm, etc.
source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" on this website are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.